Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, Gatell JM, Domingo P, Paredes R, Sharkey M, Palmer S, Stevenson M, Clotet B, Blanco J, Martinez-Picado J.

Nat Med. 2010 Apr;16(4):460-5. doi: 10.1038/nm.2111. Epub 2010 Mar 14.

PMID:
20228817
2.

[Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment].

Llibre JM, Martínez-Picado J.

Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:17-22. Review. Spanish.

PMID:
19572421
3.

Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1.

Evering TH, Markowitz M.

Drugs Today (Barc). 2007 Dec;43(12):865-77. doi: 10.1358/dot.2007.43.12.1146063. Review.

PMID:
18174972
4.

Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients.

Croxtall JD, Keam SJ.

Drugs. 2009 May 29;69(8):1059-75. doi: 10.2165/00003495-200969080-00007. Review.

PMID:
19496631
5.

Raltegravir: an integrase inhibitor for HIV-1.

Evering TH, Markowitz M.

Expert Opin Investig Drugs. 2008 Mar;17(3):413-22. doi: 10.1517/13543784.17.3.413 . Review.

PMID:
18321239
6.

Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection.

Anker M, Corales RB.

Expert Opin Investig Drugs. 2008 Jan;17(1):97-103. Review.

PMID:
18095922
7.

Raltegravir: in treatment-naive patients with HIV-1 infection.

Croxtall JD, Scott LJ.

Drugs. 2010 Mar 26;70(5):631-42. doi: 10.2165/11204590-000000000-00000. Review.

PMID:
20329808
8.

[Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens].

Kravchenko AV.

Ter Arkh. 2010;82(11):27-32. Review. Russian.

PMID:
21381345
9.

[Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor].

Delaugerre C.

Med Mal Infect. 2010 Sep;40 Suppl 1:S1-10. doi: 10.1016/S0399-077X(10)70001-9. Review. French.

PMID:
20800182
10.

Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.

Burger DM.

Expert Opin Drug Metab Toxicol. 2010 Sep;6(9):1151-60. doi: 10.1517/17425255.2010.513383. Review.

PMID:
20701552
11.

Reservoirs of HIV replication after successful combined antiretroviral treatment.

Belmonte L, Baré P, de Bracco MM, Ruibal-Ares BH.

Curr Med Chem. 2003 Feb;10(4):303-12. Review.

PMID:
12570703
12.

Raltegravir: the first HIV integrase inhibitor.

Cocohoba J, Dong BJ.

Clin Ther. 2008 Oct;30(10):1747-65. doi: 10.1016/j.clinthera.2008.10.012. Review.

PMID:
19014832
13.

Integrase inhibitors in the treatment of HIV-1 infection.

Powderly WG.

J Antimicrob Chemother. 2010 Dec;65(12):2485-8. doi: 10.1093/jac/dkq350. Epub 2010 Sep 18. Review.

PMID:
20852268
14.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
15.

Integrase inhibitors for the treatment of HIV infection.

Pace P, Rowley M.

Curr Opin Drug Discov Devel. 2008 Jul;11(4):471-9. Review.

PMID:
18600564
16.

Novel integrase inhibitors for HIV.

Prada N, Markowitz M.

Expert Opin Investig Drugs. 2010 Sep;19(9):1087-98. doi: 10.1517/13543784.2010.501078. Review.

PMID:
20707594
17.

[Efficacy of raltegravir: from healthy volunteers to phase III trials].

Gatell JM.

Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:29-33. Review. Spanish.

PMID:
19572423
18.

[How proviral DNA is integrated into the host cell DNA and how this process can be inhibited].

Mirambeau G.

Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:11-6. Review. Spanish.

PMID:
19572420
19.

HIV-1 integrase inhibitor resistance and its clinical implications.

Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW.

J Infect Dis. 2011 May 1;203(9):1204-14. doi: 10.1093/infdis/jir025. Review.

20.

Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection.

Shen L, Siliciano RF.

J Allergy Clin Immunol. 2008 Jul;122(1):22-8. doi: 10.1016/j.jaci.2008.05.033. Review.

PMID:
18602567

Supplemental Content

Support Center